POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

NCT00700401 · clinicaltrials.gov ↗

COMPLETED

Status

262

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: peginterferon alfa-2a [Pegasys]
DRUG: ribavirin [Copegus]

Sponsor

Hoffmann-La Roche